| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Quinoline-2-carboxylic acid targets multiple enzymes and pathways. It inhibits vesicular glutamate transport (GVT) in synaptic vesicles from rat forebrain. It also inhibits human recombinant MMP1 (52.0%), MMP2 (37.0%), MMP3 (73.0%), MMP9 (37.0%), mushroom tyrosinase (58.0%), and anthrax lethal factor (45.0%). It shows antidiabetic activity.
|
|---|---|
| ln Vitro |
In vitro, Quinoline-2-carboxylic acid inhibits vesicular glutamate transport with 34.0% activity. It shows substantial inhibitory effects on MMP1, MMP2, MMP3, MMP9, mushroom tyrosinase, and anthrax lethal factor. It exhibits antidiabetic activity and antiallergic activity by inhibiting passive cutaneous anaphylaxis in rats.
|
| ln Vivo |
In vivo, Quinoline-2-carboxylic acid demonstrates antiallergic activity by inhibiting passive cutaneous anaphylaxis in Sprague-Dawley rats, with an ID50 of 50.0 mg/kg when administered intravenously or intraperitoneally. It inhibits gluconeogenesis in perfused livers. It is a metabolite of tryptophan degradation and an endogenous metabolite.
|
| Enzyme Assay |
In vitro enzyme assays with Quinoline-2-carboxylic acid involve studying its inhibitory effects on various enzymes. Assays measure the inhibition of MMPs, tyrosinase, anthrax lethal factor, and vesicular glutamate transport. Standard protocols involve incubating the compound with enzyme preparations or synaptic vesicles and measuring activity using fluorimetric, colorimetric, or radiometric methods.
|
| Cell Assay |
In vitro cell culture experiments with Quinoline-2-carboxylic acid involve treating cells to study its effects on glutamate transport, enzyme inhibition, and cellular metabolism. Cells are treated with various concentrations, and endpoints include assessment of glutamate uptake, enzyme activity, cell viability, and metabolic changes. These experiments characterize the compound's bioactivity.
|
| Animal Protocol |
In vivo animal experiments with Quinoline-2-carboxylic acid typically involve rat models of passive cutaneous anaphylaxis to study its antiallergic activity. The compound is administered intravenously or intraperitoneally, and key endpoints include inhibition of allergic responses. It is also used in studies of gluconeogenesis in perfused livers.
|
| ADME/Pharmacokinetics |
The pharmacokinetic (PK) properties of Quinoline-2-carboxylic acid are not extensively characterized. As a small, polar molecule (molecular weight 173.17), it is expected to be absorbed and distributed throughout the body. It is a metabolite of tryptophan degradation. It is soluble in DMSO at 55 mg/mL and has a density of 1.339 g/cm3.
|
| Toxicity/Toxicokinetics |
Quinoline-2-carboxylic acid has a low to moderate toxicity profile as an endogenous metabolite. For research use, standard laboratory safety practices are sufficient. It is not considered a highly hazardous substance. It has a WGK Germany rating of 3. Comprehensive toxicology studies have not been extensively published for this compound.
|
| Additional Infomation |
Quinolinic acid is a quinoline monocarboxylic acid with its carboxyl group located at the 2-position. It is a metabolite in both humans and Saccharomyces cerevisiae. It is the conjugate acid of quinolinic acid.
Quinoline-2-carboxylic acid (Quinaldic acid) is an endogenous metabolite and metal chelator. It inhibits vesicular glutamate transport and various enzymes including MMPs and tyrosinase. It exhibits antidiabetic and antiallergic activities. It is a metabolite of tryptophan degradation. The compound is not a drug and has no therapeutic indications. It is available for laboratory research use only. |
| Molecular Formula |
C10H7NO2
|
|---|---|
| Molecular Weight |
173.17
|
| Exact Mass |
173.047
|
| CAS # |
93-10-7
|
| Related CAS # |
Quinoline-2-carboxylic acid-d6;1219802-18-2
|
| PubChem CID |
7124
|
| Appearance |
White to off-white solid powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
348.7±17.0 °C at 760 mmHg
|
| Melting Point |
156 °C
|
| Flash Point |
164.7±20.9 °C
|
| Vapour Pressure |
0.0±0.8 mmHg at 25°C
|
| Index of Refraction |
1.685
|
| LogP |
2.17
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
13
|
| Complexity |
205
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C2C(=C1)C=CC(=N2)C(=O)O
|
| InChi Key |
LOAUVZALPPNFOQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H7NO2/c12-10(13)9-6-5-7-3-1-2-4-8(7)11-9/h1-6H,(H,12,13)
|
| Chemical Name |
quinoline-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 100 mg/mL (577.47 mM)
H2O: 50 mg/mL (288.73 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (14.44 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (14.44 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (14.44 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 36.67 mg/mL (211.76 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.7747 mL | 28.8734 mL | 57.7467 mL | |
| 5 mM | 1.1549 mL | 5.7747 mL | 11.5493 mL | |
| 10 mM | 0.5775 mL | 2.8873 mL | 5.7747 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
